Coya Therapeutics, Inc. (NASDAQ: COYA)

Sector: Healthcare Industry: Biotechnology CIK: 0001835022
Market Cap 77.22 Mn
P/B 2.83
P/E -4.19
P/S 19.36
ROIC (Qtr) -74.12
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Coya Therapeutics, Inc., a clinical-stage biotechnology company (NASDAQ: COYA), operates in the biotechnology industry, focusing on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). Tregs are crucial in suppressing inflammatory responses and maintaining self-tolerance in mammals. The company's primary use of cash is to fund operating expenses, consisting of research and development expenditures and general and administrative expenditures. Coya Therapeutics expects to continue incurring significant expenses...

Read more

Investment thesis

Bull case

  • Tangible assets of 32.04M provide exceptional 15.96x coverage of deferred revenue 2.01M, showing strong service capability backing.
  • Operating cash flow of (12.14M) fully covers other non-current liabilities (916712) by 13.25x, showing strong long-term stability.
  • Strong free cash flow of (12.14M) provides 23.53x coverage of acquisition spending (515996), indicating disciplined M&A strategy.
  • Tangible assets of 32.04M provide robust 12.54x coverage of other current liabilities 2.56M, indicating strong asset backing.
  • Strong cash position of 28.13M provides 11.01x coverage of other current liabilities 2.56M, indicating excellent liquidity.

Bear case

  • Investment activities of (515996) provide weak support for R&D spending of 13.73M, which is -0.04x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Cash reserves of 28.13M provide limited coverage of acquisition spending of (515996), which is -54.52x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Operating cash flow of (12.14M) provides insufficient coverage of deferred revenue obligations of 2.01M, which is -6.05x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (12.14M) shows concerning coverage of stock compensation expenses of 3.98M, with a -3.05 ratio indicating potential earnings quality issues.
  • Operating earnings of (19.15M) show weak coverage of depreciation charges of 27360, with a -700.06 ratio indicating high capital intensity and potential reinvestment needs.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.48 11.06
EV to Cash from Ops. EV/CFO -3.91 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -2.48 -13.49
EV to EBITDA EV/EBITDA -2.31 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -3.91 25.66
EV to Market Cap EV to Market Cap 0.61 203.37
EV to Revenue EV/Rev 11.90 156.31
Price to Book Value [P/B] P/B 2.83 20.59
Price to Earnings [P/E] P/E -4.19 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Interest Coverage 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -9.43 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -72.29 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -81.67 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -92.01 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) -92.01 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -70.77 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -19.98 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -58.26 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.12 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 7.67 3.92
Current Ratio Curr Ratio (Qtr) 8.73 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Interest Cover Ratio 0.00 956.66
Times Interest Earned Times Interest Earned 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -479.60 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -480.32 -18,246.34
EBT Margin % EBT Margin % (Qtr) -480.32 -19,108.08
Gross Margin % Gross Margin % (Qtr) 100.00 -10.30
Net Profit Margin % Net Margin % (Qtr) -462.30 -19,056.96